(Q47573293)

4 February 2018

title

Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations (English)

1 reference

4 February 2018

0 references

7

1 reference

4 February 2018

Stephen J. Hopkins

8

1 reference

4 February 2018

Nancy Rothwell

9

object named as

Nancy J Rothwell

1 reference

4 February 2018

author name string

Simon R Clark

1

1 reference

4 February 2018

Catherine J McMahon

2

1 reference

4 February 2018

Iva Gueorguieva

3

1 reference

4 February 2018

Malcolm Rowland

4

1 reference

4 February 2018

Sylvia Scarth

5

1 reference

4 February 2018

Rachel Georgiou

6

1 reference

4 February 2018

publication date

8 August 2007

1 reference

4 February 2018

Journal of Cerebral Blood Flow & Metabolism

published in

1 reference

4 February 2018

volume

28

1 reference

4 February 2018

issue

2

1 reference

4 February 2018

page(s)

387-394

1 reference

4 February 2018

Interleukin-1 and neuronal injury

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Time-course of blood-brain barrier permeability changes after experimental subarachnoid haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Ventricular cerebrospinal fluid and serum concentrations of sTNFR-I, IL-1ra, and IL-6 after aneurysmal subarachnoid hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Cerebral microdialysis methodology--evaluation of 20 kDa and 100 kDa catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Analysis of subarachnoid hemorrhage according to the Japanese Standard Stroke Registry Study--incidence, outcome, and comparison with the International Subarachnoid Aneurysm Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

NXY-059 for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Endogenous interleukin-1 receptor antagonist is neuroprotective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Ventriculostomy-related infections: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Assessment of coma and impaired consciousness. A practical scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Potential mechanisms of interleukin-1 involvement in cerebral ischaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Interobserver agreement for the assessment of handicap in stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Reversible middle cerebral artery occlusion without craniectomy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

Blood-brain barrier integrity in patients with cerebral infarction investigated by computed tomography and serum-CSF-albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600537

7 January 2021

Identifiers

DOI

10.1038/SJ.JCBFM.9600537

1 reference

4 February 2018

PubMed ID

17684519

1 reference

4 February 2018